Combination Drug Delivery Approaches in Metastatic Breast Cancer

Table 5

Combination drug delivery systems based on polymeric nanoparticles.

Carrier composition	Therapeutics	Indication	Status	Targeting	References
Polymer-polymer micellar nanoparticles
PEG-PLGA	Lonidamine + Paclitaxel	MDR breast cancer	In vivo	Active; EGFR	[83]
Methoxy PEG-PLGA	Doxorubicin + Paclitaxel	Various cancer	In vitro	Passive	[84]
PEG-PLA	Paclitaxel, Etoposide, or Docetaxel + 17-AAG	Various cancer	In vitro	Active; HSP90	[85]
PEG-PLA	Combretastatin A4 + Doxorubicin	Various cancer	In vitro	Active; angiogenesis	[86]
PDMAEMA-PCL-PDMAEMA	Paclitaxel + siRNA	Prostate cancer	In vitro	Active; VEGF	[87]
Polymer-Lipid micellar nanoparticles
PEG-DSPE/PLGA	Combretastatin + Doxorubicin	Lung carcinoma	In vivo	Passive	[88]
PEG-PLA and PEG-DSPE/TPGS	Paclitaxel + 17-AAG (HSP90 inhibitor)	Ovarian cancer	In vitro	Active; HSP90	[89]
P(MDS-co-CES)	Paclitaxel + Interleukin-12 or siRNA	Breast cancer	In vivo	Active; Bcl-2	[90]
PEG-b-PHSA	Doxorubicin + Wortmannin	Breast cancer	In vitro	Passive	[91]
Nonmicellar polymeric nanoparticles
PLGA	Vincristine + Verapamil	Hepatocellular carcinoma	In vitro	Passive	[92]
PACA	Doxorubicin + Cyclosporine A	Various cancer	In vitro	Passive	[93]

17-AAG: 17-allylamino-17-demethyoxygeldanamycin; EGFR: epidermal growth factor receptor; HSP90: heat shock protein; PDMAEMA-PCL-PDMAEMA: poly(N,N-dimethylamino-2-ethyl methacrylate)-polycaprolactone-poly(N,N-dimethylamino-2-ethyl methacrylate); PEG: polyethylene glycol; PEG-b-PHSA: PEG-block-poly(N-hexyl stearate l-aspartamide); PEG-PLA: polyethylene glycol-poly lactic acid; PEG-DSPE: PEG-distearoylphosphatidyl ethanolamine; PACA: polyalkylcyanoacrylate; PLGA: poly(d,l-lactide-co-glycolide); P(MDS-co-CES): poly(N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbonylamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate; TPGS: tocopheryl polyethylene glycol; VEGF: vasculature epidermal growth factor.